CYP46A1 and glaucoma: These evaluations, along with EFV treatment and characterization of Cyp46a1−/− mice, revealed the novel APOJ-24HC/CYP46A1 link and suggested a principally new therapeutic approach for reducing glaucoma risk factors based on CYP46A1 activation with low-dose anti-HIV drug EFV.